Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 


Final Agenda 


Integrated RD Informatics 

Day 1 | Day 2 | Day 3 | Download Brochure 

Recommended Pre-Conference Short Courses * 

(SC3) Best Practices in Translational & Personalized Medicine 

(SC9) Building an Ontological Framework from Drug Discovery to Clinical Data  


* Separate Registration Required. 



Wednesday, February 23 

7:00 am Registration and Morning Coffee

8:00 Plenary Keynotes - Details 

9:40 Grand Opening Refreshment Break in the Exhibit Hall



KEYNOTE SESSION: Getting More Value and Generating Knowledge from Large Volumes of Data and Studies

11:00 Chairperson’s Opening Remarks

Kevin Davies, Ph.D., Author, The $1,000 Genome; Editor-in-Chief, Bio-IT World

11:10 Generating More Knowledge from Our Data and More Value from Our Studies: The Value of Expert Skills

Anastasia M. Khoury Christianson, Ph.D., Senior Director, Discovery Information, AstraZeneca Pharmaceuticals

A major challenge in translational science is finding the relevant data, information and knowledge to allow meaningful correlation between pre-clinical observations and clinical outcomes. A big factor in this challenge is that the business drivers, processes, approaches, and cultures are very different between early stages of drug discovery and late stages of drug development, which lead to very different approaches to information management systems, data standards and vocabularies.  A simple generalization is that Discovery systems and processes are designed for data exploration, while those in development are designed for regulatory submission, two very different objectives.  This presentation will concentrate on the key success factors for leveraging information, generating new knowledge, and ensuring best informed decisions in our drug projects.

11:40 Burn the Hay or Build a Better Magnet to Find the Needles in our Haystack?

Leach MartinMartin Leach, Ph.D., Executive Director, IT for Discovery & Pre-Clinical Sciences (DPS), Merck

More silos, exponential data growth, it's not going away. Lab technologies are constantly evolving and the volume and granularity of research data is ever-changing—where biological research is a much more diverse space than chemistry. Some predictions estimate that by 2011 the cost of a personal petabyte disk could be less than $1000. That equates to 20 million four-drawer filing cabinets filled with text. The expense and availability of technology enables compulsive hoarding, but at what cost to research? The ability to find things now relies heavily on search technology, data-mining or semantic-mining techniques that require proper classification of the structured and unstructured data, information, and knowledge. Search technology may be able to find things, but how do we effectively manage this information vs. constantly compounding the problem. There are several approaches that are needed in pharmaceutical research for effective information management and access and this presentation will explore some of the lessons learned at Merck and other organizations. 

12:10 pm From Virtual Machine to Virtual Pharmaceutical Organization: Cloud-Based Translational Informatics for European IMI Projects

Eric PerakslisEric Perakslis, Ph.D., Vice President, Research & Development IT, Johnson & Johnson

Anthony Rowe, Ph.D., Department of Computing, Imperial College, London

In this talk, we illustrate the design of the IT infrastructure for collaborative translational research in the UBIOPRED IMI project. The system is based on the Cloud computing infrastructure, with a strong focus on supporting open collaborative research. Through this work, we would like to demonstrate that the convergence of the technical trend in cloud computing and the industry trend in pre-competitive collaboration will realize a powerful new generation of IT infrastructure. Such an infrastructure is essential for the new knowledge-oriented scientific business where ‘proprietary data’ can be made shared to enable the collaboration in generating ‘proprietary knowledge’ for each collaborative partner from the shared data and IT infrastructure.


    Sponsored by
Biofortis smaller
12:40 Luncheon Presentation

Complex Questions Against Complex Data: Challenges in Translational and Clinical Informatics
Jian Wang, Ph.D., CEO, BioFortis, Inc.There are many unique challenges faced by research informatics groups when dealing with complex clinical and translational data sets. These challenges are exacerbated by the fact that researchers are asking increasingly more dynamic and complex questions against these data sets. Traditional BI (business intelligence) methods have their limitations under these conditions.  In this presentation, we will describe these unique challenges and BioFortis’ innovative approach to help address them, focusing on a repeatable process we developed in data cleaning & standardization, data exploration, and data analysis from working with our partners & clients.


1:10 Luncheon Presentation (Sponsorship Opportunities Available) or Lunch on Your Own

1:45 Dessert in the Exhibit Hall



2:15 Chairperson’s Remarks

Michael S. Lajiness, Ph.D., Principal Scientist, Structural & Computational Sciences, Eli Lilly & Co.

2:20 Integrating Knowledge from the Bench, Literature and the Clinic: Successes and Challenges

Bryan Takasaki, Ph.D., IS Informatics Science Director, R&D Information, AstraZeneca

The Knowledge Engineering initiative within AstraZeneca has recently delivered the first version of a platform that integrates internal and external evidence for connections between key concepts such as targets, pathways, compounds, diseases and clinical outcome. This talk will describe the impact of this new platform and lessons learned during its development.

2:50 Integrated Information & Informatics to Drive Drug Discovery

Michael S. Lajiness, Ph.D., Principal Scientist, Structural & Computational Sciences, Eli Lilly & Co. 

One of the most important but often unmet needs in pharmaceutical drug discovery is simple access to data in an integrated and effective manner.  While few off-the-shelf products exist, the ability of companies to develop custom solutions often fails.  This work will describe Mobius, an integrated information system developed internally at Eli Lilly and Company to meet a variety of data delivery needs to support Drug Discovery efforts.  Mobius is used routinely by over 1,000 scientists and allows access to over 10 million structures (Lilly and external compounds), thousands of assay results (internal and external), as well as a variety of other information.  In addition, Mobius accesses data from over 73 Oracle schemas and 18 instances. We will describe and illustrate some of the capabilities of Mobius and describe some of the software architecture behind it.

3:20 Building a Translational Biomarker Data Mining and Data Warehouse Platform: Considerations

Daniel IngberDaniel Ingber, Senior Manager, Research & Development Information Systems, MedImmune

Biomarker Data Mining (BDM) will lead to a better understanding of drug action, an improved ability to understand physiological responses, and better overview of interrelationships between research and clinical data. MedImmune just completed building a BDM and Data Warehouse platform to extract, transform, and load (ETL) data from various disparate storage locations and formats.  These include sources such as current databases and spreadsheets, from which are assembled and presented correlated data for exploratory analyses. This talk presents considerations on how to build and manage a system with a flexible data model which supports a scalable, industrial-strength scientific data pipeline.


3:50       Sponsored byAccelrysThe Pipeline Pilot NGS Collection: A New Approach to the Challenges of NGS Data AnalysisClifford Baron, Product Marketing Director, AccelrysIn repeated surveys, scientists using next generation sequencing technologies report that data analysis is their greatest challenge, and the most significant impediment to continued market growth. This is so despite the availability of over a dozen commercial software offerings and literally hundreds of public domain NGS algorithms, with more appearing weekly. The most frequently discussed factor contributing to the data analysis challenge is the sheer volume of data generated. But as significant though less frequently acknowledged is the rapid evolution of available algorithms and attendant computational best practices, and the need for techniques tailored to specific research goals. We discuss how Pipeline Pilot, a widely used commercial software system for the rapid development and deployment of computational pipelines, can be used along with a newly released collection of NGS analysis components to address these fundamental challenges.  

      Sponsored by
4:05 A Customizable Biomarker Discovery SystemIlya Mazo, Ph.D., CEO, Ariadne GenomicsFinding all the relevant facts from the vast diversity of published literature on a specific research topic continues to be a time-consuming challenge.  Transforming this information into knowledge useable by a diverse set of scientists has lead to large investments in information science.  Often these solutions have limited flexibility and extendibility.  Ariadne developed a system that capitalizes on knowledge extraction to interpret and integrate information from public and legacy sources including disease associations, druggability, mechanisms of action and toxicity, and experimental data. The system is very flexible and extendable across different domains; Target ID, lead Opt, Preclinical, Clinical development. The customization of this practical knowledge management solution to meet oncology-specific domains will be discussed with the focus on biomarker candidate identification.


4:20 Reception in the Exhibit Hall (Sponsorship Available) 

5:20 - 6:20 Breakout Discussions in the Exhibit Hall

Concurrent Problem Solving Break-Out Sessions are interactive, problem solving discussions hosted by a moderator to discuss a topic in depth.  The discussions are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in. 

Workflow-Based Informatics

David Sedlock, Ph.D., Senior Director, R&D Systems, Millennium Pharmaceuticals, The Takeda Oncology Company

  • How are workflows used in the R&D setting?
  • Where do we apply informatics solutions to workflow management?
  • What are some of the tools used to manage workflows?
  • Do we see process improvements when using these tools?

Building Ontologies

Elgar Pichler, Ph.D., Computational Biologist, Boston

  • Do we need ontologies and if so, what are (un)satisfied needs for ontologies in the health care and life sciences space?
  • Technological, organizational, and personal problems in collaborative development and sharing of ontologies
  • Ontology resources

Clinical Data Integration 

Carol Hill, Ph.D., Informatics Project Leader II, Clinical Data Integration, Duke Clinical Research Institute

  • What are barriers to integrating and sharing clinical data (cultural, legal/ethical, technical)?
  • How do standards help/hinder data integration?
  • What tools/strategies are people using to integrate clinical data across studies?
  • Challenges/experience in association to clinical information to specimens to results data sets across an enterprise

Day 1 | Day 2 | Day 3 | Download Brochure